

## PROXY FORM

in accordance with Chapter 7 Section 54 (a) of the Swedish Companies Act (2005:551)

I hereby appoint the proxy stated below, or whomever he or she may appoint, to vote on my behalf for all my shares in Calliditas Therapeutics AB (publ), Reg. No. 56659-9766, at the extraordinary general meeting of Calliditas Therapeutics AB (publ) on 30 September 2024.

### Proxy

Name of the proxy	Personal identity number/Date of birth
Address	
Postal code and city	Telephone number

### Signature by the shareholder

Name of the shareholder	Personal identity number/Date of birth/Registration number
Place and date	Telephone number
Signature*	

\*If signing for a company, a clarification of signature shall be included above and an up-to-date certificate of registration (or the equivalent) shall be enclosed to the completed proxy form.

Please note that a shareholder shall give the company notice of attendance – as set out in the notice convening the meeting – even if the shareholder intends to exercise his or her voting rights through a proxy.

The completed proxy form (with any enclosures) can be sent by post to Calliditas Therapeutics AB (publ), Extraordinary General Meeting 2024, c/o Euroclear Sweden, Box 191, SE-101 23 Stockholm, Sweden, or via e-mail to [GeneralMeetingService@euroclear.com](mailto:GeneralMeetingService@euroclear.com), so that it has been received by Euroclear Sweden AB no later than 27 September 2024. A proxy form that has been sent in without the advance voting form is not valid as a notice of participation in the general meeting. For the avoidance of doubt, if the shareholder does *not* intend to exercise his or her voting rights through a proxy, the proxy form does not have to be sent to the company.

#### Processing of personal data

For information on how your personal data is processed, please see

<https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf>